Organization
F2G Biotech
3 clinical trials
Clinical trial
Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus SpeciesStatus: Recruiting, Estimated PCD: 2024-09-14
Clinical trial
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal ImpairmentStatus: Completed, Estimated PCD: 2022-12-13
Clinical trial
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment OptionsStatus: Recruiting, Estimated PCD: 2022-09-02